Chronic gout: Epidemiology, disease progression, treatment and disease burden

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2813-2821

  Brook, Richard A ^a   Forsythe, Anna ^b   Smeeding, James E ^c   Lawrence Edwards, N ^d  

^a JeSTARx Group   (United States)

^b Savient Pharmaceuticals   (United States)

^c JestaRx Group   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Comorbidities; Costs; Epidemiology; Gout; Hyperuricemia; Urate lowering therapies; Xanthine oxidase inhibitors

Indexed keywords

URATE;

ADULT; AGE DISTRIBUTION; AGED; AGING; CHRONIC DISEASE; COMORBIDITY; COST OF ILLNESS; DIET; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; ECONOMIC ASPECT; EPIDEMIC; FEMALE; GENDER; GOUT; HUMAN; HYPERURICEMIA; INCIDENCE; LIFESTYLE; MALE; NOTE; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; UNITED STATES; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COST OF ILLNESS; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; PREVALENCE;

EID: 78349268274     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.533647     Document Type: Note

References (54)

1. National Center for Chronic Disease Prevention and Health Promotion. Arthritis. Available at: http://www.cdc.gov/arthritis/basics/gout.htm [Last accessed 17 May 2010]
2. Kim K, Schumacher R, Hunsche E, et al. A literature review of the epidemiology and treatment of gout. Clin Ther 2003;25:1593-617
3. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
4. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002;40:37-42
5. Weaver A. Epidemiology of gout. Cleveland Clinic J Med 2008;Suppl. 5:S9-12
6. Richette P, Bardin T. Gout. Lancet 2010;375:318-28
7. Choi H, Atkinson K, Karlson E, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81
8. Choi H, Atkinson K, Karlson E, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103
9. Stamp L, Searle M, O'Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs 2005;65:2593-611
10. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:865-8
11. Singh JA, Quality of life and quality of care for patients with gout. Current Rheumatology Reports 2009;11:154-60
12. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006;22:1381-9
13. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7
14. Choi H, Atkinson K, Karlson E, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men. The Health Professionals Follow-up Study. Arch Intern Med 2005;165:742-8
15. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6
16. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46
17. Choi H, Mount D, Reginato A. Pathogenesis of gout. Ann Intern Med 2005;143:499-516
18. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991;59:364-8
19. National Kidney and Urologic Diseases National Clearinghouse (NKUDIC). Available at: http://kidney.niddk.nih.gov/ [Last accessed 17 May 2010]
20. Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005;80:1383-91
21. Novak S, Melkonian AK, Patel PA, et al. Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use. Curr Med Res Opin 2007;23:623-30
22. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59:925-34
23. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006; 8(Suppl. 1):S4
24. Watt I, Middlemiss H. The radiology of gout. Clin Radiol 1975;26:27-36
25. Bloch C, Hermann G, Yu TF. A radiologic reevaluation of gout: a study of 2,000 patients. AJR Am J Roentgenol 1980;134:781-7
26. Dalbeth N, Clark B, McQueen F, et al. Validation of a radiographic damage index in chronic gout. Arthritis Rheum. 2007;57:1067-73
27. Schumacher HR, Wortmann RL. Monosodium urate crystal deposition arthropathy. Part 1: review of the stages and diagnosis of gout. Adv Stud Med 2005;5:133-8
28. Teng GG, Nair R, Saag KG. Pathophysiology, clinical presentation and treatment of gout. Drugs 2006;66:1547-63
29. McDonald E, Marino C. Stopping progression to tophaceous gout. When and how to use urate-lowering therapy. Postgrad Med 1998;104:117-20, 123-4,127
30. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80
31. Alvarez-Nemegyei J, Cen-Pisté JC, Medina-Escobedo M, et al. Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout. J Rheumatol 2005;32:1923-7
32. Hall AP, Barry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967;42:27-37
33. Wu E, Patel P, Yu A, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009; 36:1032-40
34. Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol 2008;20:198-202
35. Kerr LD. Inflammatory arthritis in the elderly. Mt Sinai J Med 2003;70:23-6
36. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guidelines for the management of gout. Rheumatology 2007;46:1372-4
37. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24
38. Sarawate C, Patel P, Schumacher R, et al. Serum urate levels and gout flares - analysis from managed care data. J Clin Rheumatol 2006;12:61-5
39. Schlesinger N. Management of acute and chronic gouty arthritis. Present state-of-the-art. Drugs 2004;64:2399-416
40. Sarawate C, Brewer K, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34
41. Mikuls R, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuri-caemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005;44:1038-42
42. Perez-Ruiz F, Carmona L, Pascual E, et al. The treatment of gout: results from the GEMA audit of clinical practice. Abstract 24, Arthritis Rheum 2008; 60(Suppl.):S177
43. O'Brien WR, Keenan RT, Crittenden DB, et al. Prevalence of co-morbidities and relative contraindications to standard therapies in a cohort of gout patients. Program and abstracts of the American College of Rheumatology (ACR) 2008 Annual Scientific Meeting; October 24-29, 2008; San Francisco, California. Abstract F92
44. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82
45. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60
46. Puig JG, Casas EA, Ramos TH, et al. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J Rheumatol 1989;16:842-4
47. Gutié rrez-Mac?́as A, Lizarralde-Palacios E, Mart?́nez-Odriozola P, et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyper-uricaemia. BMJ 2005;331: 623-4.
48. Schumacher Jr HR, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188-94
49. Strand V, Crawford B, Singh J, et al. Use of 'spydergrams' to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4
50. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009;21:132-7
51. Wu E, Patel P, Yu A, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008;14:164-75
52. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health 2007;10:231-7
53. Edwards NL, Blume S, Pan F, et al. Work productivity loss due to flares in treatment-failure gout (TFG). Arthritis Rheum 2008; 58(Suppl.):S673
54. World Health Organization (WHO). Revision of the International Classification of Diseases (ICD). Available at: http://www.who.int/ classifications/icd/ ICDRevision/en/index.html [Last accessed 17 May 2010]